Tailored Exercise Training Study Among Adults With HFpEF
Recruiting
Phase 2
Phase 3
Interventional Study
HFpEF - Heart Failure With Preserved Ejection Fraction
Diabetic Cardiomyopathies
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- University of Texas Southwestern Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of deat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age\>= 18 yrs
2. LVEF (Left Ventricular Ejection Fraction) \>= 50%
3. History of HFpEF or at risk of HFpEF
1. HFpEF diagnosis based on:- -HF hospitalization within 12 months-
* NT-proBNP \>360 pg/mL
2. Risk of HFpEF based on:-
* \>2 risk factors (h/o diab…
Contacts
No contact information available.